DJ BioCardia Shares Up 18% >BCDA
By Michael Dabaie
BioCardia Inc. (BCDA) shares were up 18% to $5.95 in heavier-than-average volume Tuesday.
Dawson James Securities initiated the company, which is developing biologic therapies to treat cardiovascular disease, at Buy with a $24 price target.
BioCardia said Monday that the independent Data Safety Monitoring Board has completed its data review for the Phase III pivotal CardiAMP Heart Failure Trial. The board indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, BioCardia said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 17, 2019 12:49 ET (16:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
DJ BioCardia股價上漲18%>BCDA
邁克爾·達巴伊(Michael Dabaie)著
BioCardia公司週二，BCDA股價上漲18%，至5.95美元，成交量高於平均水平。
道森·詹姆斯證券(Dawson James Securities)創立了該公司，目前正在開發治療心血管疾病的生物療法，目標價格為24美元。
BioCardia週一説，獨立的數據安全監測委員會已經完成了對第三階段關鍵的心臟型AMP心力衰竭試驗的數據審查。BioCardia説，董事會表示，心臟AMP研究結果不存在安全問題，並建議繼續試驗。
給Michael Dabaie寫信：michael.dabaie@wsj.com
(結束)道瓊斯通訊社
September 17, 2019 12:49 ET (16:49 GMT)
版權所有(C)2019道瓊斯公司
